FDA
-
-
-
-
-
-
-
Quoin Pharmaceuticals Announces FDA Clearance of Clinical Optimization Plan for QRX003 for Netherton Syndrome
-
-
-
-
-
-
-
Quoin Pharmaceuticals Announces Plans to Initiate a Second Clinical Trial in Netherton Syndrome Patients
-
-
-
-
-
-
-
Quoin Pharmaceuticals: Strategically Building For Future Success
-
-
-
-
-
-
-
Quoin Pharmaceuticals Announces FDA Clearance of IND for its Lead Asset, QRX003, for Netherton Syndrome
-
-
-
-
-
-
-
Pre-Open Stock Movers 12/15: (QNRX) (GMTX) (GRTX) Higher; (RBLX) (LESL) (MGNI) Lower (more...)
-
-
251,705 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All